Lupin launches generic version of Apriso
Pharma major Lupin announced the launch of authorized generic version of Bausch Health’s Apriso (Mesalamine Extended-Release Capsules 0.375 g) in the U.S.
Mesalamine Extended-Release Capsules 0.375 g (authorized generic version) are indicated for the maintenance of remission of ulcerative colitis in patients 18 years of age and older.
Also read: Cipla submits ANDA with USFDA for generic asthma drug
Extended-Release Capsules
Mesalamine Extended-Release Capsules 0.375 g. Apriso had an annual sales of approximately USD 290 million in the US (IQVIA MAT March 2020).
The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.
